Her father is David Radcliffe, a retired professor of education at the University of Western Ontario.
After Johns Hopkins, Radcliffe joined SmithKline Beecham Pharmaceuticals as a research and development policy analyst in the company's alliance and technology group.
She was also employed by the Pharmaceutical Research and Manufacturers of America (PhRMA) where she worked as senior director of biologic & biotechnology and assistant vice president of pre-clinical drug safety evaluation.
[4][5] At PhRMA, she advocated for technologies in DNA research, including testifying before the United States Congress.
[6] The CLSA was formed in conjunction with her appointment with the merger of the California Healthcare Institute and BayBIO, officially launching in 2015.